Biogen Inc. share price logo

Biogen Inc.

NASDAQ: BIIB

Large Cap

$202.95

-4.98

(-2.40%)

as on

Biogen Inc. Stock Performance

as on August 1, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $202.57
    $208.05
    downward going graph

    0.19%

    Downside

    2.51%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $124.56
    $219.72
    downward going graph

    38.63%

    Downside

    8.26%

    Upside

    downward going graph

Biogen Inc. share price movements today

Previous Close
$207.93
Open
$207.51
Volume
626.7K
Day's Low - High
$202.57 - $208.05
52 Week Low - High
$124.56 - $219.72

Biogen Inc. Historical Returns

1 Month Return
-6.09 %
3 Month Return
+ 8.49 %
1 Year Return
+ 53.81 %
3 Year Return
-25.27 %
5 Year Return
-38.82 %

Biogen Inc. Stock Fundamentals & Key Indicators

Check Biogen Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$30.7B

EPS (TTM)

12.4567

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.85%

PE Ratio (TTM)

36.93

Industry PE ratio

-15.71875

PEG Ratio

5.0607

EBITDA

3.0B

Revenue (TTM)

10.0B

Profit Margin

8.32%

Return On Equity TTM

4.58%

Biogen Inc. Stock Valuation

Track how Biogen Inc. P/E has moved over time to understand its valuation trends.

Biogen Inc. in the last 5 years

  • Overview

  • Trends

Lowest (7.78x)

June 30, 2025

Industry (-15.72x)

August 2, 2026

Today (36.93x)

August 2, 2026

Highest (18.33x)

June 30, 2023

LowHigh

Today’s Price to Earnings Ratio: 36.93x

Biogen Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Biogen Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Biogen Inc. image
Biogen Inc.
BUY$30.7B-38.82%36.938.32%NA
Eli Lilly & Co. image
Eli Lilly & Co.
BUY$1.0T365.87%42.9234.99%0.51%
AstraZeneca PLC image
AstraZeneca PLC
BUY$268.8B195.64%25.9617.02%1.26%
ABBVIE INC. image
ABBVIE INC.
BUY$454.8B117.36%130.015.79%2.56%
Johnson & Johnson image
Johnson & Johnson
BUY$616.5B48.81%30.7821.48%1.97%
See all

Stock Returns calculator for Biogen Inc. Stock including INR - Dollar returns

The Biogen Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Biogen Inc. investment value today

Current value as on today

₹1,68,167

Returns

₹68,167

(+68.17%)

Returns from Biogen Inc. Stock

₹53,808 (+53.81%)

Dollar Impact

₹14,359 (+14.36%)

Analyst Recommendation on Biogen Inc. Stock

Based on 42 analysts

BUY

71.43%

Buy

28.57%

Hold

0.00%

Sell

Based on 42 analysts, 71.43% of analysts recommend a 'BUY' rating for Biogen Inc.. Average target price of $233.87

Biogen Inc. Share Price Target

Get share price movements and forecasts by analysts on Biogen Inc..

What analysts predicted

13.22%UPSIDE

Target Price

$233.87

Current Price

$202.95

Analyzed by

42 Analysts

Target

$233.87

Biogen Inc. target price $233.87, a slight upside of 13.22% compared to current price of $202.95. According to 42 analysts rating.

Indian Investors' Interest in Biogen Inc. Stock

Search interest for Biogen Inc. Stock has increased by 7% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:7% versus previous 30 day period

Biogen Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
2,290
2,464
2,465
2,454
2,431
2,645
2,454
2,279
2,477
2,736
Gross Profit
1,792
1,509
1,827
1,871
1,853
1,699
1,578
1,783
1,816
1,557
Operating Income
690
366
577
509
732
588
613
-57
397
318
EBITDA
779
968
714
691
865
1,109
826
212
553
78
Interest Expense
69
61
59
60
60
72
67
67
67
82
Depreciation
147
158
182
184
183
194
202
200
204
236
Income Before Tax
464
698
451
291
311
744
557
-211
377
132
Income Tax Expense
71
115
62
24
70
109
90
-162
58
34
Net Income
393
583
388
266
240
634
466
-48
319
97
Net Profit Margin
17.18%
23.68%
15.76%
10.86%
9.89%
24.00%
19.00%
-2.12%
12.89%
3.56%

Biogen Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
11,448
12,273
13,452
14,377
13,444
10,981
10,173
9,835
9,675
9,810
Gross Profit
10,015
10,643
11,636
12,422
11,639
8,872
7,895
7,302
7,365
6,913
Operating Income
5,151
5,345
5,888
7,042
4,593
2,791
2,889
2,097
2,490
1,877
EBITDA
6,346
6,607
7,014
7,739
5,108
3,923
3,536
2,377
2,995
3,100
Interest Expense
260
250
200
187
222
253
246
246
250
246
Depreciation
-
1,081
1,016
680
457
487
365
494
673
779
Income Before Tax
4,933
5,128
5,899
7,046
5,052
1,780
3,594
1,296
1,906
1,401
Income Tax Expense
1,237
2,458
1,425
1,158
992
52
632
135
273
108
Net Income
3,702
2,539
4,430
5,888
4,000
1,556
3,046
1,161
1,632
1,293
Net Profit Margin
32.34%
20.69%
32.93%
40.96%
29.76%
14.17%
29.95%
11.81%
16.87%
13.18%

Biogen Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
583
388
266
240
634
466
-48
319
-319
Operating Cash Flow
625
935
760
259
160
1,272
511
645
448
Investing Cash Flow
466
-1,181
-18
-47
-57
-35
-1,231
-209
-3,839
Financing Cash Flow
-245
-6
7
-23
-11
-130
-136
-43
1,351
Change in Cash
834
-209
675
223
160
1,104
-856
374
-2,042

Biogen Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
2,670
4,474
5,888
4,060
1,727
2,961
1,161
1,632
1,292
Operating Cash Flow
4,551
6,187
7,078
4,229
3,639
1,384
1,547
2,875
2,204
Investing Cash Flow
-2,963
-2,046
470
-608
-563
1,589
-4,088
-799
-1,371
Financing Cash Flow
-2,380
-4,472
-5,860
-5,272
-2,086
-1,759
137
-683
-301
Change in Cash
-752
-349
1,689
-1,582
930
1,157
-2,369
1,325
633

Mutual Funds that own Biogen Inc. Stock

Check out the Mutual Funds with significant holdings in Biogen Inc..

Funds
Holdings
Shares Held
Motilal Oswal S&P 500 Index Fund Direct Growth
Motilal Oswal S&P 500 Index Fund Direct Growth
0.04909%
1077

Global Institutional Holdings in Biogen Inc.

Funds
Holdings
NORGES BANK
1.79%
Point72 Asset Management, L.P.
1.91%
Amvescap Plc.
1.18%
Northern Trust Corp
0.98%
Vanguard Capital Management, LLC
6.46%
See all

Biogen Inc. News & Key Events

  • img

    Today's Timeline - 29 July

    Wed, 11:06 PM

    -

    Biogen raises fiscal 2026 earnings guidance after beating revenue estimates, driven by growth in Alzheimer's and rare disease portfolio.

Insights on Biogen Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 2.27B → 2.73B (in $), with an average increase of 8.7% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, BIIB stock has moved up by 53.8%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, AstraZeneca PLC has given 129.4% return, outperforming this stock by 75.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Eli Lilly & Co. has given 137.4% return, outperforming this stock by 162.0%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 319.49M → 97.50M (in $), with an average decrease of 69.5% per quarter

About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
OrganisationBiogen Inc.
Headquarters225 Binney Street, Cambridge, MA, United States, 02142
IndustryDrug Manufacturers - General
CEOMr. Christopher A. Viehbacher
E-voting on sharesClick here to vote

Key Management of Biogen Inc.

Name

Title

Mr. Adam Keeney Ph.D.

Executive VP & Head of Corporate Development

Dr. Ginger Gregory Ph.D.

Executive VP & Chief Human Resources Officer

Mr. Christopher A. Viehbacher

President, CEO & Director

Dr. Priya Singhal M.D., M.P.H.

Executive VP & Head of Development

Mr. Sean Godbout

VP, Chief Accounting Officer & Global Corporate Controller

Mr. Tim Power M.B.A., Ph.D.

Head of Investor Relations

Ms. Robin C. Kramer

Executive VP & CFO

Ms. Nicole Murphy

Executive VP and Head of Pharmaceutical Operations & Technology

Mr. Guy Hadari

Chief Information Officer

Ms. Natacha Gassenbach

Chief Communication Officer & Head of Corporate Affairs

FAQs

What is Biogen Inc. share price today?

Biogen Inc. share price today is $202.95 as on at the close of the market. Biogen Inc. share today touched a day high of $208.05 and a low of $202.57.

What is the 52 week high and 52 week low for Biogen Inc. share?

Biogen Inc. share touched a 52 week high of $219.72 on and a 52 week low of $124.56 on . Biogen Inc. stock price today i.e. is closed at $202.95,which is 7.63% down from its 52 week high and 62.94% up from its 52 week low.

What is Biogen Inc.'s market capitalisation today?

Biogen Inc. market capitalisation is $0.03T as on .

How to invest in Biogen Inc. Stock (BIIB) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Biogen Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Biogen Inc. Shares that will get you 0.0074 shares as per Biogen Inc. share price of $202.95 per share as on August 1, 2026 at 8:46 am IST.

What is the minimum amount required to buy Biogen Inc. Stock (BIIB) from India?

Indian investors can start investing in Biogen Inc. (BIIB) shares with as little as ₹95.39 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.90 in Biogen Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Biogen Inc. share’s latest price of $202.95 as on August 1, 2026 at 8:46 am IST, you will get 0.0493 shares of Biogen Inc.. Learn more about fractional shares .

What are the returns that Biogen Inc. has given to Indian investors in the last 5 years?

Biogen Inc. stock has given -38.82% share price returns and 28.64% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?